| Compugen Announces Positive Therapeutic Effects Of Relaxin Receptor Peptide Ligand In Pulmonary Fibrosis Animal Model (Medical News Today) |
|
|
Compugen (NASDAQ:CGEN) announced that CGEN-25009, a novel peptide that previously demonstrated the ability to activate the Relaxin receptor LGR7 (RXFP1) in cell based assays, has shown positive therapeutic effects in an animal model of pulmonary fibrosis. |